The FDA challenge for regulating CBD
Recent warning letters and Consumer Updates from the FDA have sent a chill through the CBD industry. Anticipated market entrants like Coca-Cola, Mondelez, Starbucks and Kellogg’s that would have bought up much of the CBD inventory produced from a record-year of hemp cultivation have mostly stayed on the sidelines, leading to a precipitous fall in hemp and hemp derivative prices. This regulatory uncertainty is leading CBD companies to come up with novel approaches to develop and market their products while staying afloat in this volatile market. Join Sarah as she discusses what the current FDA position on CBD is, projected regulatory rules and pathways, existing CBD products and their ability to market medical claims including OTC monograph topicals, and the role of individual states in regulating CBD, THC and minor cannabinoids.